Denikitug (NCT07546812)

Name: Denikitug trial for HER2-negative (NCT07546812)
Uploaded: 2026-10-31T15:24:50.616Z
Duration: 1 min 31 s
Description: Denikitug trial for HER2-negative (NCT07546812). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07546812.

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas: a one-minute explainerNCT075468121 min

Denikitug trial for HER2-negative (NCT07546812). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced HER2-negative stomach, gastroesophageal-junction or esophageal adenocarcinoma after first-line treatment. MSI-high or mismatch-repair-deficient tumors are excluded. PD-L1-positive tumors require prior PD-1/PD-L1 therapy.

The idea: test denikitug infusions alone, with nivolumab, or with ramucirumab and paclitaxel. Denikitug targets CCR8-bearing immune-suppressing cells, aiming to restore antitumor immunity. Treatment differs by part; the chemotherapy combination requires a safety group before expansion. Researchers measure responses and safety. Prior VEGF-pathway treatment excludes participation.

This phase 2 study plans 120 patients. Gilead sponsors three recruiting US sites in Boston, Albany and New York.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.